| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Mark J Alles last filed a Form 4 in September 2023, as Director at BMRN. The filings on record cover 2 companies. Mark J Alles's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 15,095 shares of BMRN. Net of sales, the BMRN filings show accumulation of 3,625 shares.
Mark J Alles has 12 Form 4 filings on record from December 2019 to September 2023, across 2 companies: Director at Syros Pharmaceuticals (SYRS), 2019–2023; Director at Biomarin Pharmaceutical (BMRN), 2022–2023.
The 14 reported transactions were 8 option or other derivative awards, 3 stock awards, 2 open-market purchases and 1 option exercise.
Counted by filing, the open-market trades come to 2 purchases worth about $403K and no sales.
The largest open-market purchase was 3,625 shares of BMRN at an average $86.75 on October 31, 2022, about $314K. Twelve months later BMRN was down 6%.
Shares as reported in the last Form 4 for each company; the most recent is from September 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.